Medicare's GLP-1 Bridge puts branded GLP-1s at $50 a month

Medicare began covering three branded GLP-1 weight-loss drugs at $50 a month on July 1 through a time-limited initiative called the Medicare GLP-1 Bridge. It is open only to some people with Part D drug coverage, and Medicare's own rules for who qualifies are narrower and stranger than the headline price suggests. WeightWatchers said the day before that its Med+ program will help members use it.

What happened

In its launch announcement on July 1, the Centers for Medicare & Medicaid Services called the Medicare GLP-1 Bridge "a new Centers for Medicare & Medicaid Services (CMS) initiative designed to expand access to innovative treatments and test the impacts of increased access to GLP-1 drugs for weight management on the Medicare program," and said it "will remain available through December 31, 2027." CMS added that "Not all Medicare beneficiaries will qualify for the Medicare GLP-1 Bridge, including individuals who already receive GLP-1 medications through their existing Medicare prescription drug coverage or are eligible for GLP-1 coverage through the Medicare Part D benefit." CMS Administrator Mehmet Oz said the Bridge "creates a new pathway for eligible beneficiaries to afford GLP-1 medications."

Medicare's own fact sheet, CMS Product No. 12234, dated June 2026, is the document that names the drugs. It lists Foundayo (tablet), Wegovy (injection or tablet), and "Zepbound (KwikPen only)," and adds a warning in the same line: "The single-dose Zepbound pen and Zepbound vials are NOT covered." The format matters as much as the molecule here. The fact sheet also states the price plainly — "$50 per month, no matter your income level" — and then the catch: "This $50 payment doesn't count toward your Medicare drug plan deductible or yearly out-of-pocket limit. These drugs aren't eligible for the Medicare Prescription Payment Plan." The $50 is also not available on a first trip to the counter. After the pharmacy confirms eligibility, the fact sheet says "your doctor will need to submit a form to get approval from Medicare for coverage," and Medicare then sends a letter confirming the drug is covered.

Eligibility is where this program is counterintuitive, so we quote it rather than summarize it. The fact sheet says a beneficiary must meet "all four of these requirements." The first is Medicare Part D drug coverage, "under either a standalone Medicare Drug Plan or a Medicare health plan that includes drug coverage" — and Medicare attaches an exclusion to it: "You're not eligible if your only Medicare coverage is through certain special plan types (like private fee-for-service plans, cost contract plans or a PACE organization)." The second is being "not eligible to receive a GLP-1 drug through your Medicare drug plan," which Medicare defines by ingredient: "Semaglutide, Tirzepatide, Orforglipron, Dulaglutide, and Liraglutide." The third is that you "don't have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease." The fourth is being "at least 18 years of age" and meeting one of three thresholds: "a Body Mass Index (BMI) of 35 or higher"; "BMI is 30 or higher, and you have certain types of heart failure OR high blood pressure that's hard to control OR chronic kidney disease (stage 3a or above)"; or "BMI is 27 or higher, and you have prediabetes OR you've had a heart attack, stroke or blocked arteries in your legs or arms." Read the second and third together: conditions that normally make GLP-1 coverage easier to obtain are what disqualify you from the Bridge, because CMS expects your Part D plan to cover you already.

WeightWatchers announced on June 30, a day before the program opened, that Med+ now supports members who want to use it. Its release says that "to qualify for the Medicare Bridge program, you must have Medicare Part D, meet clinical eligibility, and have a prescription for an eligible GLP-1 medication," and offers prescription management, insurance navigation and prior-authorization help. Chief Commercial Officer Scott Honken said the goal is "to make the process feel less overwhelming by helping members understand their options, access care and receive a GLP-1 prescription if they're eligible." One detail in that release does not match Medicare's: it lists the covered drugs as "Zepbound, KwikPen, Foundayo, and Wegovy pen and pill," which reads as though Zepbound in any form is covered. Medicare's fact sheet is explicit that it is the KwikPen only.

Why it matters

Against what our readers actually pay, $50 is not a discount, it is a different market. Novo Nordisk's own multi-month subscriptions, which we covered in April, bottom out at $249/mo for the Wegovy pen or the pill, and only on a prepaid 12-month commitment. Our price database holds cheaper branded Wegovy than that, $149/mo at Sesame Care and at Hims & Hers, and $98/mo at Fridays on a prepaid annual plan, and our tirzepatide cost guide starts lower still, at $79/mo for Noom's compounded microdose plan. Even so, $50 undercuts every self-pay price we hold for the three drugs the Bridge names: our cheapest branded Zepbound is $299/mo and our cheapest Foundayo is $149/mo.

The catch for WeightWatchers members is that the Bridge prices the medication, not the program around it. In our database, WeightWatchers' Med+ GLP-1 program is a separate monthly fee with medication billed separately, and "higher all-in cost" is already a listed con in our WeightWatchers review, where the brand scores 60.0 overall and 55 on value. A $50 medication cost does not remove that fee; it changes what the fee is buying.

One caution about our own tools. Our GLP-1 eligibility checker applies the FDA-labeled criteria that telehealth programs use — a BMI of 30, or 27 with a weight-related condition. Those are not the Bridge's criteria, and the Bridge excludes two of the conditions our checker treats as qualifying. Passing our checker tells you nothing about whether Medicare will approve you. We also have no medication page for Foundayo yet; we covered its approval in April and it is the newest of the three.

What this means for patients

• Do not assume you qualify on the price alone. Medicare says you must meet "all four" requirements on its fact sheet, including having no type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease. Call 1-800-MEDICARE or your drug plan to check; a telehealth brand's marketing page is not the authority on this.
• Check the format, not just the brand name. Medicare covers the Zepbound KwikPen and says the single-dose pen and the vials are not covered. If you are already being supplied a Zepbound vial, that is a different product than the one this program pays for.
• Ask what the $50 does not do. It does not count toward your Part D deductible or your yearly out-of-pocket limit, and these drugs are excluded from the Medicare Prescription Payment Plan.
• If you are already getting a GLP-1 through your Part D plan, Medicare says to keep getting it that way — you are not eligible for the Bridge.
• The program is scheduled to end December 31, 2027. Ask your prescriber and your plan what happens to your cost after that date before you build a budget around $50.
• If you use a telehealth program to coordinate this, price the program fee separately from the medication. Compare what you would pay elsewhere on our weight-loss alternatives to WeightWatchers page.